ArticleCureus2026
Graft-Versus-Host Disease After Liver Transplantation: Diagnostic and Therapeutic Challenges.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-versus-host disease (GVHD) is a rare but severe complication following solid organ transplantation, with limited literature guiding diagnosis and management. We present a 55-year-old man with alcohol-associated end-stage liver disease who developed GVHD approximately one month after orthotopic liver transplantation (LT). He was initially admitted for persistent fever and concern for sepsis, with subsequent development of progressive pancytopenia and a non-pruritic maculopapular rash with mucosal involvement. Skin biopsy performed on hospital day 10 supported the diagnosis of GVHD, and donor chimerism testing demonstrated 70% donor-derived CD3+ lymphocytes. He improved with high-dose intravenous methylprednisolone and remained clinically stable on ruxolitinib maintenance therapy at two-month post-discharge follow-up. GVHD following LT should be considered early in patients with non-specific presentations, such as unexplained fever, cytopenias, rash, or mucosal findings. Early recognition, tissue biopsy, and chimerism testing may facilitate timely intervention and improve outcomes in this rare condition associated with high mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.